GLP-1 T 60mg
Dual GIP/GLP-1 Agonist
Tirzepatide is a dual GIP and GLP-1 receptor agonist—the most powerful FDA-approved weight loss medication available. Available in multiple concentrations.
The Science
What is Tirzepatide?
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. Unlike single-action medications, tirzepatide activates two hormone pathways simultaneously for superior weight loss results.
The dual mechanism targets both appetite regulation and metabolic function. GIP activation enhances the effects of GLP-1, resulting in greater satiety, improved blood sugar control, and more significant fat reduction than GLP-1-only medications.
Laboratory Observations
Key Observed Effects of GLP-1 T 60mg
Superior Weight Loss
Clinical trials showed participants lost an average of 22.5% of their body weight—47% more than semaglutide in head-to-head trials.
Dual Hormone Action
Works on two hormone pathways (GIP + GLP-1) simultaneously for enhanced appetite suppression and metabolic improvement.
Blood Sugar Control
Excellent for pre-diabetes prevention with significant improvements in fasting glucose and HbA1c levels.
Cardiovascular Benefits
Studies show improvements in blood pressure, cholesterol, and waist circumference—key cardiovascular risk factors.
Mechanism of Action
The Dual GIP/GLP-1 Mechanism
Tirzepatide’s dual-action approach delivers superior results through multiple pathways.
GIP Receptor Activation
Activates GIP receptors to enhance fat metabolism, improve insulin sensitivity, and amplify the weight loss effects of GLP-1—delivering results beyond single-pathway medications.
GLP-1 Receptor Activation
Stimulates GLP-1 receptors in the brain to reduce appetite, slow gastric emptying, and promote prolonged satiety—supporting feelings of satisfied with smaller portions.
Metabolic Enhancement
Improves blood sugar regulation, reduces insulin resistance, and supports healthier lipid profiles—benefits that extend well beyond weight loss alone.
FAQ
Frequently Asked Questions
How does tirzepatide compare to semaglutide?+
Tirzepatide works on two hormone receptors (GIP + GLP-1) while semaglutide only targets GLP-1. In the SURMOUNT-5 head-to-head trial, tirzepatide achieved 20.2% average weight loss compared to 13.7% with semaglutide—47% greater relative weight loss. The investigator can help determine which is best for goals.
Research-Only Notice
GLP-1 T 60mg is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.